This article does not advertise a prescription-only medicine or imply that a named treatment is available from the clinic. Treatment decisions require an individual medical consultation.
Which scientific approaches are being studied?
Major directions include dual and triple receptor agonism, GLP-1 and amylin combinations, glucagon-containing combinations, oral small-molecule GLP-1 agonists and less frequent dosing.
- Retatrutide: triple GIP, GLP-1 and glucagon receptor agonist; phase 3 programme
- CagriSema: cagrilintide and semaglutide combination; phase 3 programme
- Survodutide: glucagon and GLP-1 receptor agonist; phase 3 programme
- Orforglipron: oral small-molecule GLP-1 receptor agonist; phase 3 programme
- Maridebart cafraglutide: long-acting GIP-receptor antibody conjugate; phase 3 programme reported
- Amycretin: amylin and GLP-1 receptor agonism; clinical development
What else are trials trying to improve?
Research is examining maintenance, cardiovascular, kidney and liver outcomes, treatment convenience and the preservation of health during weight loss.
A lower dosing frequency or larger average weight change does not automatically make a treatment better for an individual. Tolerability, safety, access, licensing and long-term outcomes remain important.
How should pipeline announcements be interpreted?
Peer-reviewed results provide more detail than company announcements, while trial registries clarify protocol and status.
Manufacturer announcements may describe preliminary findings but should not be the sole basis for a patient-facing clinical claim. None of the research programmes listed here is presented as available from Dr K Medical Wellness.
Frequently asked questions
No. Phase 3 is an advanced research stage, but regulators may request further evidence or decline an application.
No. New mechanisms can be promising, but established safety, individual suitability and long-term outcomes matter.
References
- ClinicalTrials.gov. Clinical trial registry search: obesity pharmacotherapy. Live registry. Registered clinical-trial records. Accessed 12 June 2026.
- PubMed. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025. Peer-reviewed phase 3 randomised controlled trial. Accessed 12 June 2026.
- New England Journal of Medicine. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. 2023. Peer-reviewed phase 2 randomised controlled trial. DOI: 10.1056/NEJMoa2301972. Accessed 12 June 2026.